1-855-378-42281-855-378-4228
One of the outpatient rehabilitation alternatives for clients in Calvin struggling with opioid abuse and addiction is called opioid maintenance therapy. Licensed clinics and doctors are certified to administer specific medications to opioid addicted individuals, many of which are opioids also and are addiction. In low amounts however, the client doesn't experience high feelings and also does not have acute cravings and is not in opioid withdrawal. Methadone is the first medication tried for this purpose, but there are alternative choices currently to pick from.
Methadone is an opiate and can be taken at an out-patient medical center licensed to dispense the drug, that is taken on a daily basis as a pill or liquid. The price of the med is around $150 per month. Buprenorphine is also an opioid based med, and is in pill form often taken one day on, one day off. But different from Methadone that can only be dispensed in highly structured clinics, Buprenorphine can be and is prescribed and dispensed in doctor's offices. The price monthly of buprenorphine is approximately $300.00 /month for the generic of the drug. There is also a version of buprenorphine that contains the ingredient naloxone, that is a med that reverses the effects of opiates. A person consuming this version of the drug, also known as Suboxone, would find it more difficult to get high from opioids if they relapsed while taking the drug. It too is taken every day, and costs approximately $450 /month. Naltrexone is an additional med taken in opioid maintenance therapy, but unlike the other medications aforementioned it is an opiate blocker and isn't an opioid. A person has the choice to take this drug as a monthly injection, which is called Vivitrol. As an opioid blocker, the drug prevents an individual from experience high feelings from opioids, and in turn lowers the risk associated with relapse. This daily shot costs in the range of $1000 to $1200 /month.
For All Alcohol and Drug Treatment Facilities In Calvin, Click Here.
